New drug PVT201 tested for safety in liver patients
Knowledge-focused
Completed
This early-phase study tested a single dose of PVT201 in 24 people to see if it is safe and how the body processes it. Healthy volunteers and patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) took part. The goal was to check for side effects …
Phase: PHASE1 • Sponsor: Parvus Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 08:18 UTC